Introduction
In 1938, Dorothy Andersen first described the clinical spectrum that characterized cystic fibrosis (CF) as a distinct disease entity.' This was soon followed by the realization that CF was a genetic disease with a recessive pattern of inheritance.2 In 1989, the cystic fibrosis transmembrane conductance regulator (CFTR) gene sequence was identified on chromosome seven; mutation of which is linked to the disease described in Andersen's paper.3 Despite recognition of the genetic defect, the diagnosis of cystic fibrosis still remains a challenge in a significant number of cases. This paper will explore the various reasons for this and discuss the challenges in establishing a diagnosis of cystic fibrosis, focusing in particular on atypical forms of the disease.
What is cystic fibrosis?
The product of the CFTR gene is an important protein, which co-ordinates salt transport across epithelia.4 Disruption of CFTR function has distinct consequences for different parts of the body and certain organs seem to be more sensitive than others. 5 The widespread presence of CFTR throughout the body *Correspondence: Dr Kevin Southern, Institute of Child Health, University of Liverpool, Royal Liverpool Children's Hospital, Eaton Road, Alder Hey, Liverpool L12 2AP, UK E-mail: kwsouth@liv.ac.uk (the lungs, salivary glands, pancreas, liver, sweat ducts and reproductive tract) helps to explain why CF is a multisystem condition affecting many organs. The two major systems affected are the lungs and the gastrointestinal tract.
Before considering atypical forms of cystic fibrosis, it is important to reflect on what constitutes 'classical CF'. The standard clinical combination is lung disease (through deranged airway clearance) and malabsorption of food (through pancreatic dysfunction). Cystic fibrosis is also characterized by increased sweat sodium and chloride concentration, a feature which was recognized early in this condition.6 Measurement of sweat electrolytes has long been established as an important tool for the diagnosis of CF and sample collection was simplified in 1959 by the development of a method for sweat stimulation utilizing pilocarpine iontophoresis.7 The diagnosis of 'classic CF' has since rested on demonstration of characteristic clinical features (distinctive lung infections, bowel blockage in a neonate, evidence of malabsorption or rectal prolapse) with raised sweat electrolytes (traditionally a sweat chloride of more than 60 mmol L 1).
A variable phenotype
The fact that cystic fibrosis can be associated with a variable phenotype was also recognized at an early stage in the history of the condition.8 A small but significant number of children with chest disease and raised sweat electrolytes are not affected by malabsorption (termed pancreatic sufficient). In general, although not always, these children have milder lung disease than those who are pancreatic insufficient. We now know that pancreatic sufficient patients are more likely to have a mutation oftheir CFTR gene that results in some residual protein function (although again this is not a consistent rule).9 It would appear that different organs have different susceptibility to CFTR dysfunction, in effect the sweat gland is more susceptible than the airway, which in tum is more susceptible than the pancreas.5 However, the situation is probably more complex and different CFTR mutations may affect different organs in distinct ways (e.g., the mutation S 1455X causes an isolated abnormality of sweat gland function, 10 discussed later). What is also becoming increasingly apparent is that other genes modify the phenotypic expression of cystic fibrosis, therefore two children with exactly the same CFTR genotype can have very different phenotypes.11 The final important factor determining phenotype and disease severity is environment, for example, a previously well child with CF exposed to a particular pathogen (e.g., Burkholderia cepacia comflex) may rapidly develop profound CF lung disease.
Establishing a diagnosis
Despite the inherent variability in disease expression and severity, establishing a diagnosis is straightforward in the vast majority of children with cystic fibrosis. It is a continuing disappointment to hear families recount the experience of numerous consultations with health care workers prior to diagnosis. Paediatricians and primary care physicians must continue to have a low threshold for suspecting a diagnosis of cystic fibrosis even in children without classic symptoms (e.g., respiratory symptoms but reasonable weight gain velocity). This is particularly important in areas that run a newborn screening programme.13 No newborn screening test for CF is fully sensitive and infants may move from a non screening to a screening area.
Mutations of the CFTR gene
In the Caucasian population, one mutation of the CFTR gene is predominant. This mutation, AF508, is a codon deletion and accounts for the vast majority of affected CFTR alleles (in the UK population approximately 70% of all alleles).14 Why AF508 has been such a successful mutation remains unclear although some heterozygote advantage to tolerate diarrhoeal illness is the most convincing hypothesis. The prevalence of Chronic Respiratory Disease other CFTR mutations is much lower and dependent on geographical and cultural factors.
Sweat testing
If two mutations are recognized it is still important to undertake sweat testing to confirm a diagnosis of CF. When two mutations are not recognized the sweat test becomes key to diagnosis. It is essential that the sweat test be undertaken in an accredited centre, that a sufficient flow rate of sweat is produced and that the test is repeated to confirm an abnormal result. A recent working party convened by the UK CF Trust has produced a comprehensive evidence based guideline for the performance of a sweat test (for further information visit: http://www.acb.org.uk/Guidelines/ sweat. htm).15 They have focused on issues of standard procedures and validation of centres. They suggest that sweat Clremains the gold standard measure in difficult cases. The need for sweat testing to be performed in centres with adequate experience is highlighted.
An abnormal genotype with a normal phenotype
Over 1000 changes to the CFTR gene have been recognized. The vast majority are disease-causing mutations, however some appear to have little if any phenotypic consequence. Two relatively common mutations merit further discussion. The first, a point mutation, RI 17H, results in replacement of an arginine amino acid with histidine at position 117 in the CFTR protein (the first part of the protein that spans the cell membrane). The second is a reduction in the number of thymidine bases in the splicing site at the end of intron 8 of the CFTR gene. The standard number of thymidine bases at this point is seven (although nine is a normal variant). Occasionally there are only five, which results in inefficient splicing of intron 8, with subsequent reduction in the production and expression of CFTR messenger RNA. A recent paper highlighted that splicing of intron 8 can be further compromized by an increase in the number of TG repeats adjacent to the poly T region (TG repeats are a common sequence in splicing regions).16 People with 12 or 13 TG repeats next to a 5T allele are far more likely to have severe CFTR-related disease than those with 11 TG repeats.
The 5T allele has been associated with infertility in men [congenital bilateral absence of the vas deferens (CBAVD)], 17 and with a CF phenotype when associated with a CFTR mutation on the other allele. RI 17H is associated with a milder spectrum of disease. From a molecular perspective this relates to the fact that a full length ofprotein is produced, which is transported appropriately to the cell membrane, where it functions (albeit at a lower level), as a chloride channel (this type of mutation is termed class IV).18 Rl 17H can coexist with a 5T variant on the same allele. This double hit on CFTR production and function invariably results in a more severe or 'classic' CF phenotype. However RI 17H can also coexist with a 7T variant. Some infants with this genotype have a normal phenotype (including a normal concentration of Clin the sweat) even with a severe CFTR mutation such as AF508 on the other allele. It is extremely difficult to know how to counsel the families of these infants. 19 Evidence from adult practice suggests that people with this genotype may have significant CF lung disease later in life.20 In addition, male infants may go on to have infertility issues in adult life. 21 The term 'pre-CF' has been advocated but this may be problematic from a psychological and social perspective. 22 Assignment of a CF diagnosis has significant social consequences even if the person enjoys good health. People with a CF diagnosis are finding it increasingly difficult to obtain reasonable travel insurance and mortgages. Given that R117H is one of the more common CFTR mutations and is often associated with a severe phenotype, it will continue to be included in most newborn screening programmes that employ DNA analysis. A significant proportion of infants with this mutation will have 'classic' CF, however, the recognition of infants with RI 17H on a 7T background will continue to pose a clinical dilemma to CF teams and clinical geneticists. The conclusions of a consensus group in the USA suggested that such children did not constitute a CF diagnosis.23 Our current practice is to review these infants on an annual basis having discussed the issues at length with the families. RI 17H and the 5T variant are two common CFTR abnormalities that cause confusion, however there are other less common variations in the sequence of the CFTR that can present with an atypical phenotype. For example, another splice site mutation (3849 + 10 kb C > T) and other class IV mutations (e.g., I1 19V, R334W and P67L) have been associated with borderline sweat tests. Much useful information regarding all reported CFTR mutations can be accessed at the Toronto-based Cystic Fibrosis Mutation Database web site (http://www.genet.sickkids.on.ca/cgi-bin/ WebObjects/MUTATION).
An abnormal sweat test without CF
A number of conditions can give rise to raised sweat electrolytes, particularly in the unwell child (septicae-Diagnosis of cystic fibrosis KW Southern and D Peckham 207 mia and oedema).24 Certain metabolic and endocrine disorders have been associated with CF and care must be taken in interpreting results from children with inflamed skin from, for example, eczema. One mutation of the CFTR gene (S 1455X) results in an abnormal sweat test but no other phenotypic evidence of CF.10 This is a nonsense mutation that results in a truncated CFTR protein with the final 26 amino acids missing. Absence of these amino acids does not appear to adversely affect CFTR production or function aside from in the sweat gland where this section of the protein seems to have a role.
An abnormal phenotype with a normal genotype Some children may present with clinical features suggestive of cystic fibrosis but the recognition of only one CFTR mutation (or occasionally none at all). These children may have raised sweat electrolytes in the range associated with a CF diagnosis (sweat Cl >60 mmol L 1). In these cases it must be assumed that they have an as of yet unrecognized CFTR mutation and a diagnosis of CF in the circumstance of raised sweat electrolytes with clinical features is reasonable.23 The sweat test, however, must be performed in an accredited centre and on more than one occasion. One group has suggested it is possible to have a CF phenotype with a completely normal CFTR genotype, (i.e., after comprehensive sequencing of the gene, they have not recognized an abnormality). 25 Interestingly, children referred to this group with one recognized mutation would often have another identified following the extensive CFTR gene sequencing, however, children in whom no mutation had been recognized nearly always failed to have any subsequent mutations identified. Although this group sequenced all the exons, only small areas of intronic DNA and very few areas outside the CFTR gene were sequenced, leaving the possibility of unrecognized mutations. These findings were presented as evidence of a 'CF-like' disease with normal CFTR gene. To support this the group reported two families with children who presented with very similar CF phenotypes (including moderately raised sweat Cl-).
In both families these children had inherited different CFTR alleles from their mother, suggesting that the cause of the condition lay outside this allele. This is a significant paradigm shift and one which requires further investigation.
A challenging and not uncommon scenario is the child presenting with clinical features of CF and an equivocal sweat Cl-(between 30 and 60 mmol L 1). These children require careful evaluation in a specialist www.CRDjournal.com centre that can provide alternative physiological measures of CFTR function to the sweat test, such as nasal potential difference measurement. First, these children require a thorough clinical evaluation. If they have persistent chest radiograph abnormalities and respiratory signs or symptoms, then bronchoscopy and bronchoalveolar lavage may identify pathogens associated with CF (e.g., Pseudomonas aeruginosa). In addition, a computerized tomogram scan may identify bronchiectasis not recognized on the chest radiograph.26 Careful assessment for fat malabsorption is essential, including analysing faeces for fats, chymotrypsin and faecal elastase. Evidence of fats on faecal microscopy may prompt a more formal three-day faecal fat collection (a difficult and unreliable investigation). Low chymotrypsin and particularly low faecal elastase are consistent with pancreatic insufficiency.27 In addition to these indirect tests of pancreatic function; imaging of the pancreas (plain abdominal radiograph, ultrasound scan or computerized tomogram scan) may demonstrate evidence of pancreatic fibrosis or calcification. Finally it may be appropriate in males to examine for evidence of vas deferens, though obviously this would require counselling and empathy.
It is important that these children have complete DNA analysis for CFTR mutations and not just a standard screen. Unusual gene defects (e.g., a duplication) may be overlooked if not specifically targeted. Many molecular genetic laboratories now offer complete sequencing of the CFTR gene. Mutations may lie outside the CFTR gene affecting promoter regions and levels of CFTR expression (as discussed above). Again sweat testing needs to be undertaken in an accredited centre and repeated on at least two occasions. In children with clinical features of CF, but equivocal sweat tests and inconclusive DNA analysis, it is appropriate to undertake further investigations examining CFTR ion transport function. A number of assays exist, including measurements of ion transport in tissue obtained from the gastrointestinal tract, either small bowel or rectal mucosa.28'29 CFTR is expressed in high levels in the distal gut epithelium and data suggests that a good differentiation between non-CF and CF mucosa is possible.30
However obtaining rectal or small bowel biopsies is a challenge. Consequently measurement of ion transport across the proximal airway epithelia in the nose is a more widespread test. Nasal potential difference measurement The active transport of charged ions across the electrically tight respiratory epithelia results in a Chronic Respiratory Disease 'voltage' or potential difference (PD).31 As Na+ absorption is the principal ion transport of the airway, the PD is negative when viewed from the outside. In CF, Na+ hyperabsorption and Climpermeability result in: 1) a high negative baseline PD; 2) the magnitude of which falls precipitously following perfusion with a solution that blocks Na+ absorption (amiloride); and 3) a lack of response to a solution that stimulates Clsecretion. In the non-CF airway the baseline PD is lower, the fall with amiloride less and the rise in PD with Cl-secretion often considerable.32'33 It can be seen therefore that there are two distinct patterns of nasal PD, distinguishing CF from non-CF airways (Figure 1) . However, the situation is not straightforward and people with classical CF occasionally have evidence of Clsecretion. 34 In addition, people with PD (mV) CF may have a low baseline PD, particularly if their nasal epithelia is inflamed.
Overall there is clear differentiation between the CF and non-CF pattem and the nasal PD measurement provides a useful insight into airway ion transport. In a significant number of individuals with an equivocal sweat test, nasal PD measurement can provide useful information towards making or refuting a diagnosis of cystic fibrosis. However, it is not unusual to have an equivocal nasal PD result [e.g., a low baseline PD but with no evidence of chloride secretion or a high baseline PD (>-40 mV) with evidence of chloride secretion (>-10 mV)]. Some advocate repeating this test and it is important that the result is seen in the context of other investigations. Again nasal PD needs to be undertaken in a centre with experience of regularly undertaking this procedure.23
Establishing the diagnosis in the adult clinic
This has become an increasingly regular occurrence. Not surprisingly most of these patients have a mild disease phenotype and are often pancreatic sufficient, however, adults with quite severe disease are sometimes recognized. The diagnosis is most often recognized through identification of two disease associated CFTR mutations.
There are some particular features about diagnosing CF in the adult clinic that deserve consideration. First, sweat electrolytes are higher in adults than in children and therefore a sweat Clin the 40-60 range may not be significant, but certainly warrants repeating and consideration given to undertaking further measures of CFTR function. Sweat testing is not a standard procedure in some adult-orientated hospitals and in such cases referral to an accredited centre is important. Equivocal sweat tests are more common and the finding of sweat Cl higher than sweat Na+ concentration (which is a frequent finding in classic CF) may not apply. 35 Secondly, unusual presentations of CF are more likely and high index of suspicion should exist for adults presenting with monosymptomatic disease (e.g., nasal polyps, pancreatitis, bronchiectasis and CBAVD). Finally, in men thorough assessment of the vas deferens (including ultrasound scan) is imperative, although the sensitivity of the situation must be appreciated, particularly if he already has a child.
Congenital bilateral absence of the vas deferens
Obstructive azoospermia is virtually universal in men with CF. A number of research groups examined for CFTR mutations in men attending infertility clinics. A high prevalence of CFTR mutations in this population in particular the 5T allele was found.'7 Many now consider CBAVD an 'atypical' form of CF and certainly more extensive clinical evaluation has revealed evidence of lung disease and raised sweat electrolytes in a significant number of these men. The assumption from these findings is that the vas deferens is extremely sensitive to CFTR dysfunction.
Pancreatitis
Pancreatitits is rare in CF individuals who are pancreatic insufficient (who require pancreatic enzyme supplements) but does occur more frequently than expected in CF individuals who are pancreatic sufficient. Again DNA analysis on people with idiopathic pancreatitis demonstrated a significantly increased prevalence of CFTR mutations, again raising the possibility that some idiopathic pancreatitis reflects an atypical form of CF.363 Increased prevalence of CFTR mutation has also been reported for isolated rhinosinusitis38 and allergic bronchopulmonary aspergillosis,39 although the evidence that these conditions represent atypical forms of CF is less convincing.
Conclusion
In the majority of cases, establishing a diagnosis of CF is straightforward, however, in a significant number it remains challenging. This reflects the heterogeneous nature of CF and, whilst identification of the putative gene defect has given much insight into this condition, grey areas persist. It is important that physicians are mindful of the spectrum of disease presentations that reflect CFTR dysfunction and that a meticulous and methodical approach is adopted for the evaluation of patients with an atypical presentation. Individuals and their families require clear and honest information in order to come to terms with their circumstances. This requires detailed consultations in the first instance and regular review subsequently in a clinic setting, albeit not on a frequent basis.
